Annual Total Long Term Liabilities
$36.48 B
-$1.95 B-5.08%
31 March 2024
Summary:
Takeda Pharmaceutical Company Limited annual total long term liabilities is currently $36.48 billion, with the most recent change of -$1.95 billion (-5.08%) on 31 March 2024. During the last 3 years, it has fallen by -$17.56 billion (-32.50%). TAK annual total long term liabilities is now -33.37% below its all-time high of $54.76 billion, reached on 31 March 2020.TAK Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$36.86 B
-$195.94 M-0.53%
01 September 2024
Summary:
Takeda Pharmaceutical Company Limited quarterly total long term liabilities is currently $36.86 billion, with the most recent change of -$195.94 million (-0.53%) on 01 September 2024. Over the past year, it has increased by +$489.53 million (+1.35%). TAK quarterly long term liabilities is now -40.37% below its all-time high of $61.81 billion, reached on 30 June 2019.TAK Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TAK Long Term Liabilities Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -5.1% | +1.4% |
3 y3 years | -32.5% | -22.4% |
5 y5 years | -33.2% | -37.6% |
TAK Long Term Liabilities High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -32.5% | at low | -23.7% | +1.4% |
5 y | 5 years | -33.4% | at low | -37.6% | +1.4% |
alltime | all time | -33.4% | +3617.6% | -40.4% | +1458.0% |
Takeda Pharmaceutical Company Limited Long Term Liabilities History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $36.86 B(-0.5%) |
June 2024 | - | $37.06 B(+1.6%) |
Mar 2024 | $36.48 B(-5.1%) | $36.48 B(-1.0%) |
Dec 2023 | - | $36.86 B(+1.3%) |
Sept 2023 | - | $36.37 B(-1.9%) |
June 2023 | - | $37.08 B(-3.5%) |
Mar 2023 | $38.43 B(-12.3%) | $38.43 B(-1.0%) |
Dec 2022 | - | $38.83 B(+2.3%) |
Sept 2022 | - | $37.96 B(-7.1%) |
June 2022 | - | $40.86 B(-6.8%) |
Mar 2022 | $43.82 B(-18.9%) | $43.82 B(-9.3%) |
Dec 2021 | - | $48.29 B(+1.7%) |
Sept 2021 | - | $47.50 B(-8.1%) |
June 2021 | - | $51.67 B(-4.4%) |
Mar 2021 | $54.04 B(-1.3%) | $54.04 B(-4.6%) |
Dec 2020 | - | $56.64 B(-0.9%) |
Sept 2020 | - | $57.14 B(+4.4%) |
June 2020 | - | $54.76 B(-0.0%) |
Mar 2020 | $54.76 B(+0.3%) | $54.76 B(-1.1%) |
Dec 2019 | - | $55.35 B(-6.3%) |
Sept 2019 | - | $59.06 B(-4.5%) |
June 2019 | - | $61.81 B(+13.2%) |
Mar 2019 | $54.60 B(+329.3%) | $54.60 B(+111.2%) |
Dec 2018 | - | $25.85 B(+133.6%) |
Sept 2018 | - | $11.07 B(-10.0%) |
June 2018 | - | $12.30 B(-3.3%) |
Mar 2018 | $12.72 B(+37.9%) | $12.72 B(+2.5%) |
Dec 2017 | - | $12.40 B(-2.5%) |
Sept 2017 | - | $12.72 B(+4.1%) |
June 2017 | - | $12.22 B(+32.5%) |
Mar 2017 | $9.23 B(+8.5%) | $9.23 B(-5.9%) |
Dec 2016 | - | $9.80 B(-11.0%) |
Sept 2016 | - | $11.00 B(+0.6%) |
June 2016 | - | $10.94 B(+28.7%) |
Mar 2016 | $8.50 B | $8.50 B(+0.8%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2015 | - | $8.43 B(-3.3%) |
Sept 2015 | - | $8.72 B(-0.8%) |
June 2015 | - | $8.79 B(-1.7%) |
Mar 2015 | $8.94 B(-24.9%) | $8.94 B(-14.0%) |
Dec 2014 | - | $10.40 B(-9.8%) |
Sept 2014 | - | $11.53 B(-5.9%) |
June 2014 | - | $12.25 B(+2.9%) |
Mar 2014 | $11.91 B(+3.8%) | $11.91 B(-10.2%) |
Dec 2013 | - | $13.26 B(-4.5%) |
Sept 2013 | - | $13.89 B(+22.9%) |
June 2013 | - | $11.31 B(-1.5%) |
Mar 2013 | $11.47 B(+39.0%) | $11.47 B(-9.4%) |
Dec 2012 | - | $12.66 B(-3.9%) |
Sept 2012 | - | $13.17 B(+32.1%) |
June 2012 | - | $9.97 B(+20.8%) |
Mar 2012 | $8.25 B(+222.1%) | $8.25 B(+52.9%) |
Dec 2011 | - | $5.40 B(-5.2%) |
Sept 2011 | - | $5.69 B(+121.3%) |
June 2011 | - | $2.57 B(+0.5%) |
Mar 2011 | $2.56 B(+4.2%) | $2.56 B(-1.7%) |
Dec 2010 | - | $2.61 B(-0.6%) |
Sept 2010 | - | $2.62 B(+0.3%) |
June 2010 | - | $2.61 B(+6.3%) |
Mar 2010 | $2.46 B(+3.9%) | $2.46 B(+3.9%) |
Dec 2009 | - | $2.37 B(-3.8%) |
Sept 2009 | - | $2.46 B(+4.0%) |
Mar 2009 | $2.37 B(+141.1%) | $2.37 B(-5.0%) |
Dec 2008 | - | $2.49 B |
Mar 2008 | $981.33 M(-31.5%) | - |
Mar 2007 | $1.43 B(-17.9%) | - |
Mar 2006 | $1.75 B(+4.8%) | - |
Mar 2005 | $1.67 B(-5.7%) | - |
Mar 2004 | $1.77 B(+41.9%) | - |
Mar 2003 | $1.25 B(-4.5%) | - |
Mar 2002 | $1.30 B(+8.2%) | - |
Mar 2001 | $1.21 B | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual total long term liabilities?
- What is the all time high annual total long term liabilities for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual total long term liabilities year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly long term liabilities year-on-year change?
What is Takeda Pharmaceutical Company Limited annual total long term liabilities?
The current annual total long term liabilities of TAK is $36.48 B
What is the all time high annual total long term liabilities for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual total long term liabilities is $54.76 B
What is Takeda Pharmaceutical Company Limited annual total long term liabilities year-on-year change?
Over the past year, TAK annual total long term liabilities has changed by -$1.95 B (-5.08%)
What is Takeda Pharmaceutical Company Limited quarterly total long term liabilities?
The current quarterly long term liabilities of TAK is $36.86 B
What is the all time high quarterly long term liabilities for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly total long term liabilities is $61.81 B
What is Takeda Pharmaceutical Company Limited quarterly long term liabilities year-on-year change?
Over the past year, TAK quarterly total long term liabilities has changed by +$489.53 M (+1.35%)